Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
PVP Ventures Ltd

| Quarterly Financial Results Q3 FY 2025-26

BEARISH SENTIMENT

Report Source

⬤23rd Feb 26

Summary : PVP Ventures reported significant losses in Q3 and 9M FY25, driven by underperforming subsidiaries, while actively pursuing strategic healthcare acquisitions and managing various legal and related-party financial complexities.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Standalone Q3 FY25: Total Expenses Rs. 1,114.05 Lakhs.
  2. Consolidated Q3 FY25: Total Expenses Rs. 1,786.31 Lakhs.
  3. Debtors turnover (No. of days): 14.01 (Standalone Q3 FY25), 4.76 (Consolidated Q3 FY25).
  4. Standalone Q3 FY25: Revenue from operations Rs. 803.72 Lakhs, Other Income Rs. 291.86 Lakhs.
  5. Consolidated Q3 FY25: Revenue from operations Rs. 1,396.40 Lakhs, Other Income Rs. 312.86 Lakhs.
  6. Consolidated 9M FY25 Segment Revenue: Real Estate Rs. 2,229.96 Lakhs, Health Care Services Rs. 2,596.77 Lakhs.
  7. GST demand of Rs. 1,375.06 Lakhs (including penalty) set aside by High Court.
  8. Revised Sub-Registrar's demand of Rs. 378.28 Lakhs, appealed and pending.
  9. SEBI penalty of Rs. 14 Lakhs for NCD compliance, appealed to SAT.
  10. Standalone Dec 2025: Paid-up equity share capital Rs. 26,040.37 Lakhs, Networth Rs. 20,484.55 Lakhs.
  11. Consolidated Dec 2025: Paid-up equity share capital Rs. 26,040.37 Lakhs, Networth Rs. 23,825.33 Lakhs.
  12. Consolidated Segment Assets Dec 2025: Real Estate Rs. 42,134.24 Lakhs, Health Care Services Rs. 14,088.13 Lakhs.
  13. Loan to NCCPL (erstwhile subsidiary, now related party) of Rs. 21,843.49 Lakhs.
  14. Sale of NCCPL stake to PHML (related party) with Rs. 2,800.00 Lakhs receivable.
  15. Acquisition of HHT from PV Potluri (related party) for Rs. 2,249.60 Lakhs.
  16. Interest-free loan to HHT (subsidiary) of Rs. 2,281.85 Lakhs.
  17. SEBI investigation on related party transactions in earlier financial years.
  18. Consolidated results show higher revenue but also higher losses compared to standalone, reflecting performance of acquired subsidiaries/associates.

Corporate Overview

  1. India (Mumbai, Chennai, Hyderabad, Telangana, Tamil Nadu)
  2. Negative net worth and continuing losses in some subsidiaries (PHML, HHT).
  3. Ongoing SEBI investigation into related party transactions.
  4. Pending appeals for tax demands and regulatory penalties.
  5. Significant related party loans and receivables (NCCPL, PHML, HHT).
  6. Real Estate development and investments.
  7. Health Care Services through subsidiaries and associates.
  8. Confident in recovering related party receivables.
  9. Optimistic about favorable outcomes in legal and regulatory matters.
  10. Real Estate
  11. Health Care Services
  12. Acquisition of 52% stake in Biohygea Global Private Limited (Medilabs).
  13. Acquisition of 56% shareholding in Optimus Oncology Private Limited.
  14. Acquisition of 33.24% stake in 7Med India Private Limited.
  15. Issuance of 15,000 Secured, Rated, Listed Non-Convertible Debentures (NCDs) aggregating Rs. 15,000 Lakhs for housing/infrastructure and real estate debt.
  16. In-principle approval for merger of Humain Healthtech Private Limited (HHT) with the Company.

Risk Factors

  1. Related party loan recovery remains uncertain.
  2. Adverse findings from SEBI investigation.
  3. Acquired subsidiaries continue to incur losses.
  4. Potential for further regulatory non-compliance.

Key Drivers

  1. Healthcare acquisitions drive future profitability.
  2. Successful resolution of all legal disputes.
  3. Effective monetization of real estate assets.
  4. Improved financial performance from subsidiaries.

Auditor’s Report

  1. Unmodified Limited Review Conclusion for standalone financial results.
  2. Unmodified Limited Review Conclusion for consolidated financial results.
  3. Review of interim financial results of 6 subsidiaries (including 2 step-down) not performed by reporting auditor; conclusion based on other auditors' reports.
  4. Provisional accounting for Medilabs and Optimus acquisitions based on unaudited financial statements at acquisition date.
  5. Certificate on security cover and compliance status of NCD covenants is for specific purposes (Debenture Trustee, SEBI) and not for general use.

Board Commentary

  1. Resignation of Mrs. P.J. Bhavani, Non-Executive Non-Independent Director, effective February 23, 2026.
  2. Reconstitution of Nomination and Remuneration Committee.
  3. Reconstitution of Non-Convertible Debenture Committee.
  4. No dividend declared due to significant losses.
  5. Dividend declaration is restricted by covenants with Debenture Holders.
  6. Uncertainty in recovering Rs. 21,843.49 Lakhs loan from NCCPL due to negative net worth.
  7. Receivable of Rs. 2,800.00 Lakhs from PHML, which has negative net worth and going concern issues.
  8. Ongoing SEBI investigation into related party transactions from earlier financial years.
  9. Impairment of Rs. 669.69 Lakhs provided for HHT investments due to negative net worth and operational suspension.
  10. Board meeting rescheduled due to statutory auditors requiring additional time for limited review and certificates.
  11. Approved Unaudited Standalone and Consolidated Financial Results for Q3 and 9M ended December 31, 2025.
  12. Approved Security Cover Certificate for the quarter ended December 31, 2025.

Corporate Governance

  1. Resignation of Non-Executive Non-Independent Director.
  2. Nomination and Remuneration Committee includes Independent Directors.
  3. Nomination and Remuneration Committee reconstituted.
  4. Non-Convertible Debenture Committee reconstituted.
  5. SEBI investigation into past related party transactions.

Management Discussion & Analysis

Future Strategy

  1. Expanding healthcare services through strategic acquisitions and integration.
  2. Actively managing and recovering related party investments and loans.
  3. Ensuring compliance with regulatory requirements and covenants.

Operational Focus Areas

  1. Resolving ongoing legal and regulatory challenges.
  2. Integrating newly acquired healthcare entities.
  3. Maintaining compliance with NCD covenants.

Performance Drivers

  1. Strategic acquisitions in the healthcare sector.
  2. Monetization of real estate assets and land bank.
  3. Funding through Non-Convertible Debenture issuance.

Risk Control Measures

  1. Management confident in recovery of related party loans based on business plans and security.
  2. Company has responded to SEBI summons, confident of favorable outcome.
  3. GST liability set aside by High Court ruling.
  4. Appeals filed for tax demands, management confident of favorable outcome.

Critical Risks

  1. Recoverability of substantial related party loans.
  2. Adverse outcomes from regulatory investigations.
  3. Continued losses from acquired subsidiaries.
  4. Potential for further tax and penalty demands.